Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03717402 · ClinicalTrials.gov registry record · NA
Smartphone Technology to Alleviate Malignant Pain (STAMP)
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT03717402 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 20 participants.
The verdict
NCT03717402, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of the study is to develop the STAMP app (Smartphone Technology to Alleviate Malignant Pain). This app will be used by patients with advanced cancer to track symptoms and receive tailored symptom management advice. This is a single arm pilot feasibility study of the application among patients with advanced cancer and chronic pain who are using opioids in the home setting. Patients will be asked to use the application for a four week period. Clinicians responsible for the patients' pain management will be asked to review alerts from the STAMP system and respond accordingly. The primary outcomes of the study relate to feasibility and acceptability.
Interventions
- BEHAVIORAL Intervention Participants
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2022-05-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03717402
The ClinicalTrials.gov registry entry for NCT03717402 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intervention Participants is the first listed.
NCT03717402 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03717402 about?
NCT03717402 is a clinical study titled "Smartphone Technology to Alleviate Malignant Pain (STAMP)". The purpose of the study is to develop the STAMP app (Smartphone Technology to Alleviate Malignant Pain). This app will be used by patients with advanced cancer to track symptoms and receive tailored symptom management advice. This is a single arm pilot feasibility study of the application among pa...
What is the current status of trial NCT03717402?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2018-11-01. Estimated completion is 2022-05-01.
What interventions are being tested in trial NCT03717402?
The interventions under investigation include: Intervention Participants (BEHAVIORAL).
Who is sponsoring clinical trial NCT03717402?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.